Zeposia (Ozanimod) Shows Durable Efficacy and Safety in Multiple Sclerosis Patients
Wednesday, 18 September 2024, 04:02
Significant Findings from the Phase 3 DAYBREAK Trial
Bristol Myers Squibb today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients receiving Zeposia (Ozanimod). This long-term data underlines the potential for durable efficacy in treating relapsing multiple sclerosis (MS).
Sustained Efficacy and Safety Outcomes
- Long-Term Data: Results indicate that the efficacy of Zeposia remains consistent over time.
- Safety Profile: Patients exhibited a stable safety profile during the OLE phase.
- Impact on Brain Health: Continuous monitoring reveals a significant reduction in brain volume loss, a critical aspect of relapsing MS management.
The findings from this study highlight Zeposia as a valuable option for those suffering from multiple sclerosis, suggesting that early treatment may lead to better long-term outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.